Figure 1: miRNA mimic screening in APAP- or FAS-induced cell death.

(a) Schematic of miRNA screening in APAP-induced toxicity in primary mouse hepatocytes. (b) Cell viability is shown as fold change of each miRNA transfection to scramble control transfection. (c) List of miRNAs that are expressed in the liver, either at high or at least moderate levels, and showed more than 20% protection against APAP-induced toxicity compared with scramble control. (d,e)GSH/GSSG assay of mouse primary hepatocytes transfected with each candidate miRNA mimic (d) or inhibitor (g), followed by APAP treatment. *P<0.05, one-way analysis of variance (ANOVA). (f) Schematic of miRNA screening in FAS-induced hepatocyte toxicity. miRNAs were transfected to primary mouse hepatocytes, followed by treatment of FAS-induced hepatocyte toxicity. (g) Cell viability is shown as fold change of each miRNA transfection to scramble control transfection. (h) List of miRNAs that are expressed in the liver either at high or at least moderate levels and showed more than 20% protection against FAS-induced hepatocyte toxicity, compared with scramble control. (i) Representative photographs (× 200 magnification) of TUNEL assay on mouse primary hepatocytes transfected with each candidate miRNA mimic or inhibitor, followed by FAS treatment. Scale bars, 100 μm. (j) Quantification of TUNEL staining shown in i *P<0.05, one-way ANOVA. Data are presented as mean±s.e.m. (n=4 per group).